Business
Uptick Newswire “Stock Day” Interviews John Poss CEO of GB Sciences on the Company’s Cannabis Tiers, Medical and Recreational
Uptick Newswire “Stock Day” Interviews John Poss CEO of GB Sciences on the Company’s Cannabis Tiers, Medical and Recreational.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n Phoenix, AZ, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Uptick Newswire is the sole producer of the Uptick Network “Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of CEO’s within the micro-cap publicly traded sector of the market bringing important updates to the investor community. The Company that joined Everett Jolly on Stock Day today is in a broad spectrum of the cannabis industry and keeps the Stock Day listeners updated regularly on where the Company is at within the industry.\n Starting off the interview Mr. Jolly introduces the returning guest and gives a great introduction to this unique Company, “The Company seeks to be an innovative technology and solutions Company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. It also plans to produce consistent and measurable medical grade cannabis, cannabis concentrates and cannabinoid therapies.” Stock Day welcomes back John Poss, CEO of GB Sciences Inc. (OTCQB:GBLX) (the “Company”) as he gives the low down on GB Sciences four cannabis tiers and explains what great importance each of these tiers hold within the Company and the cannabis industry. Continuing his explanation, Mr. Poss elaborates on the Company patents, dosing, compounds, along with much more and further explains the individual importance of the companies within GB Sciences. Mr. Jolly springs the question on Mr. Poss regarding when an investor invests into GB Sciences and Mr. Poss sheds light on that unique investment. He elaborates on that question letting investors know that they aren’t just investing into one Company but they are investing in numerous pieces of the puzzle that makes up GB Sciences as a whole. In a closings statement CEO John Poss states, “There’s one principal that drives us and helps people understand medical versus regulation simplistically we believe that every consumer of cannabis deserves to have the best cannabis, medical grade cannabis, whether they are using it for recreational purposes or specific medical purposes, everyone deserves the best and that’s what we are providing to those segments of the market.”  To listen to the full interview please click here or the following link: https://upticknewswire....